Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Stephen M AnsellPublished in: American journal of hematology (2022)
High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. For patients who fail HDCT with ASCT, brentuximab vedotin, PD-1 blockade, non-myeloablative allogeneic transplant, or participation in a clinical trial should be considered.
Keyphrases
- hodgkin lymphoma
- stem cell transplantation
- high dose
- stem cells
- clinical trial
- low dose
- bone marrow
- healthcare
- palliative care
- cell therapy
- quality improvement
- phase ii
- open label
- pain management
- study protocol
- randomized controlled trial
- platelet rich plasma
- free survival
- allogeneic hematopoietic stem cell transplantation
- phase iii
- radiation therapy
- affordable care act
- health insurance